DELRAY BEACH, Fla., Oct. 15, 2025 /PRNewswire/ -- The global Active Pharmaceutical Ingredients (API) Market, valued at US$136.22 billion in 2024, stood at US$144.20 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2025 to 2030, culminating in a forecasted valuation of US$198.39 billion by the end of the period. The growth of the active pharmaceutical ingredients market is driven by the rising surge in demand for complex APIs, government incentives & supply chain reshoring, and increasing demand for APIs for novel formulation development.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263
Browse in-depth TOC on "Active Pharmaceutical Ingredients (API) Market"
692 - Tables
65 - Figures
533 - Pages
By Potency, the global active pharmaceutical ingredients market is segmented by potency into two major segments: traditional APIs and highly potent APIs (HPAPI). Traditional API include low-potency, medium-potency, and potent APIs. Low-potency APIs form category I of the SafeBridge classification system.
The traditional APIs segment accounted for the largest share in 2024, whereas the HPAPI segment is expected to grow at the fastest CAGR over the forecast period. The HPAPI segment is further segmented into Synthetic and Biologics HPAPI. The growth of the HPAPI segment is majorly driven by the rising global burden of oncology and chronic diseases, which has significantly increased the demand for targeted and highly effective therapies. HPAPIs form the backbone of many modern cancer treatments, such as antibody-drug conjugates (ADCs) and precision small-molecule drugs, where high potency at low doses helps improve efficacy while minimizing side effects. This trend is further reinforced by the broader shift toward precision medicine, with pharmaceutical companies investing heavily in R&D pipelines that feature novel HPAPI-based candidates across oncology, immunology, and hormonal disorders. On the supply side, rapid advances in manufacturing technologies, such as continuous processing, modular high-containment facilities, and improved analytical methods, are making large-scale HPAPI production safer, more efficient, and regulatory-compliant.
By type of synthesis, the global active pharmaceutical ingredients (API) market has been segmented into synthetic APIs and biotech APIs. In 2024, the synthetic APIs segment held the largest share of the market. This dominance is mainly due to the increasing regulatory approvals for new drugs and advancements in chemical synthesis techniques. Synthetic APIs offer several advantages over large-molecule or biologic drugs. They can be designed to provide strong therapeutic effects at very small doses, often below 10 mg or even at microgram levels. The reduced quantity requirements, coupled with improvements in chemical manufacturing technologies, make synthetic APIs cost-effective while maintaining high efficacy. The analytical methods for developing synthetic APIs are highly refined, ensuring consistent quality and therapeutic performance. In contrast, innovative APIs, which include large molecules such as proteins and monoclonal antibodies, require more complex manufacturing processes and larger quantities for effective dosing, making them relatively expensive. Despite this, biotech APIs are increasingly adopted for specialized therapies targeting complex diseases. Overall, the combination of efficiency, scalability, and technological maturity keeps synthetic APIs as the dominant segment. Biotech APIs continue to grow in niche and high-value therapeutic areas, reflecting a balanced but evolving market landscape.
By geography, North America held the largest share of the global active pharmaceutical ingredients (API) market in 2024, driven by several key factors. The region benefits from a well-established pharmaceutical industry, robust infrastructure, and advanced technological capabilities, collectively supporting efficient API manufacturing and development. Regulatory frameworks in the United States and Canada are well-defined, providing clear pathways for drug approvals and ensuring high-quality standards, which encourage domestic production and foreign investments. Additionally, North America has a strong presence of leading pharmaceutical and biotechnology companies that continuously invest in research and development, driving innovation in synthetic and biotech APIs. The increasing prevalence of chronic diseases, rising demand for personalized medicines, and growth in biologics and specialty therapies further contribute to the market expansion. Advanced manufacturing technologies, such as continuous processing, process automation, and high-precision analytical methods, also enhance production efficiency and reduce costs. Moreover, the region's strong healthcare infrastructure and high per capita healthcare spending facilitate rapid adoption of new therapies, boosting API consumption. These factors position North America as a dominant player in the global API market, and the region is expected to maintain its leadership due to ongoing innovation, favorable regulations, and growing healthcare demands in the foreseeable future.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=263
Key players in the active pharmaceutical ingredients market include Pfizer (CentreOne) (US), Teva Pharmaceutical Industries Ltd. (Israel), Divi's Laboratories Limited (India), Sandoz Group AG (Switzerland), SK Inc. (South Korea), Merck KGaA (Germany), Dr. Reddy's Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma (India), Evonik Industries AG (Germany), Hikma Pharmaceuticals plc (UK), BASF SE (Germany), Alembic Pharmaceuticals Limited (India), Siegfried Holding AG (Switzerland), EUROAPI (France), Asymchem (China), Bachem (Switzerland), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), and Zhejiang Hisun (China).
Pfizer Inc. (US):
Pfizer Inc. (US) is a global pharmaceutical leader and one of the pioneers in active pharmaceutical ingredients. As one of the largest pharmaceutical companies globally, Pfizer develops and produces both small-molecule APIs and biotech APIs to support its broad therapeutic portfolio, including oncology, vaccines, cardiovascular, and anti-infective treatments. The company has invested heavily in modernizing and expanding its API manufacturing infrastructure to enhance efficiency, regulatory compliance, and supply reliability. Recent expansions, such as the large-scale API facility in Singapore, reflect its focus on strengthening global production and reducing supply chain vulnerabilities. Pfizer also emphasizes sustainable manufacturing through greener chemistry and advanced process technologies. With increasing demand for high-potency APIs, Pfizer's expertise, scale, and innovation place it at the forefront of shaping the evolving API market and meeting rising global healthcare needs.
Teva Pharmaceutical Industries Ltd. (Israel)
Teva Pharmaceuticals is one of the largest global players in the active pharmaceutical ingredients (API) market, supported by its dedicated subsidiary, Teva API. The company operates a broad network of manufacturing sites across Europe, North America, and Asia, producing over 350 APIs serving Teva's generic portfolio and external customers worldwide. It is recognized for its leadership in high-quality, cost-effective generic APIs, as well as its capabilities in complex and high-potency molecules. The company invests in advanced process technologies, green chemistry, and regulatory compliance to maintain a competitive edge in a highly regulated market. By leveraging economies of scale, Teva ensures a reliable supply to global partners. Its diversified API portfolio, long-standing expertise, and a strong focus on innovation position Teva as a key enabler in meeting the growing global demand for affordable medicines.
For more information, Inquire Now!
Related Reports:
Pharmaceutical Excipients Market
High Potency APIs Market
Pharmaceutical Contract Manufacturing Market
Contract Research Organization Services Market
Clinical Trial Supplies Market
Get access to the latest updates on Active Pharmaceutical Ingredients (API) Companies and Active Pharmaceutical Ingredients (API) Market Size
About MarketsandMarkets:
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/active-pharmaceutical-ingredients-api-market-worth-198-39-billion-by-2030-with-6-6-cagr--marketsandmarkets-302584559.html
